Analysts have mixed ratings for Anika Therapeutics (NASDAQ:ANIK) with a blend of bullish and indifferent perspectives. The average 12-month price target is $30.0, with a high of $37.00 and a low of $22.00. Recent ratings include 'Equal-Weight' and 'Outperform' with price targets ranging from $22.00 to $37.00. The company's financial performance shows a revenue growth rate of 6.85%, a net margin of -11.14%, an ROE of -2.15%, and an ROA of -1.69%.